About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer

NCT00881296·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hamamatsu University

Age

76–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer
Good performance status (ECOG 0-1)
No previous treatment
Age 76 years and older
Adequate bone marrow, liver and renal functions
No pregnant
Measurable disease, defined as at least one lesion whose longest diameter can be accurately measured as \>=1.0 cm by spiral CT scan
Provided written informed consent

You may not be if

Severe complications or a concomitant malignancy
Prior and other concurrent radiotherapy, chemotherapy, immunotherapy, EGFR tyrosine kinase inhibitors
Interstitial pneumonia or lung fibrosis
Contraindicated gemcitabine or carboplatin
Inappropriate patients for entry to this study, judged by the physicians

The record

StatusCompleted

PhasePhase 2

Taking part60

StartedMar 2008

UpdatedSep 7, 2011

Conditions

Non-Small Cell Lung Cancer

Where1

Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan

Clareo Health | Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer